Global Blood Therapeutics, Inc.
HISTONE METHYLTRANSFERASE INHIBITORS

Last updated:

Abstract:

The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinpathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Status:
Application
Type:

Utility

Filling date:

4 Nov 2020

Issue date:

15 Apr 2021